NASDAQ
110.07USD
-1.03 (-0.93%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.2B
P/E
—
EPS
—
Beta
0.08
52W range
22.81-117.88
Day range
105.05–111.28
Open
110.08
Prev close
111.10
Volume
531.9K
Avg volume
889.7K
Dividend
0.00
IPO
2018-06-21
https://seekingalpha.com/article/4939821-dianthus-therapeutics-stock-c1-shakeout-strengthens-bull-case · 8/25/2026+0.80
https://www.fool.com/coverage/filings/2026/05/17/why-this-fund-just-made-a-usd55-million-bet-on-dianthus-amid-a-350-stock-rally/ · 5/17/2026+0.80
https://www.fool.com/coverage/filings/2026/04/19/dianthus-therapeutics-dnth-cfo-sold-8-224-shares-for-usd739-000/ · 4/19/2026+0.40
https://www.etftrends.com/etf-building-blocks-content-hub/biotech-ma-spree-helps-lead-sbio-march-gains/ · 4/8/2026+0.85
https://www.defenseworld.net/2026/03/22/dianthus-therapeutics-inc-nasdaqdnth-given-consensus-recommendation-of-moderate-buy-by-brokerages.html · 3/22/2026+0.80
https://www.globenewswire.com/news-release/2026/03/11/3253481/0/en/Dianthus-Therapeutics-Inc-Announces-Pricing-of-Upsized-625-Million-Underwritten-Public-Offering.html · 3/11/2026+0.40
https://www.benzinga.com/news/health-care/26/03/51126539/dianthus-therapeutics-stock-rallies-rare-disease-study-success-fuels-optimism · 3/9/2026+1.00
https://www.defenseworld.net/2026/03/07/citigroup-inc-has-2-70-million-stock-holdings-in-dianthus-therapeutics-inc-dnth.html · 3/7/2026+0.40
https://seekingalpha.com/article/4860294-dianthus-therapeutics-inc-dnth-presents-at-44th-annual-j-p-morgan-healthcare-conference · 1/15/2026+0.10
https://www.zacks.com/stock/news/2784952/day-one-biopharmaceuticals-inc-dawn-reports-q3-loss-tops-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2784952 · 11/4/2025+0.40
https://www.globenewswire.com/news-release/2025/10/02/3160307/0/en/Dianthus-Therapeutics-Highlights-Claseprubart-Data-Presentations-Planned-for-2025-AANEM-Annual-Meeting.html · 10/2/2025+0.80
https://www.globenewswire.com/news-release/2025/09/10/3147456/0/en/Dianthus-Therapeutics-Inc-Announces-Pricing-of-Upsized-251-Million-Underwritten-Public-Offering.html · 9/10/2025+1.00
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
